1. Home
  2. VNRX vs GANX Comparison

VNRX vs GANX Comparison

Compare VNRX & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VNRX
  • GANX
  • Stock Information
  • Founded
  • VNRX N/A
  • GANX 2017
  • Country
  • VNRX United States
  • GANX United States
  • Employees
  • VNRX N/A
  • GANX N/A
  • Industry
  • VNRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • GANX Biotechnology: Pharmaceutical Preparations
  • Sector
  • VNRX Health Care
  • GANX Health Care
  • Exchange
  • VNRX Nasdaq
  • GANX Nasdaq
  • Market Cap
  • VNRX 64.8M
  • GANX 69.0M
  • IPO Year
  • VNRX N/A
  • GANX 2021
  • Fundamental
  • Price
  • VNRX $0.63
  • GANX $1.64
  • Analyst Decision
  • VNRX Strong Buy
  • GANX Strong Buy
  • Analyst Count
  • VNRX 4
  • GANX 5
  • Target Price
  • VNRX $3.50
  • GANX $8.20
  • AVG Volume (30 Days)
  • VNRX 200.3K
  • GANX 614.4K
  • Earning Date
  • VNRX 11-13-2025
  • GANX 11-13-2025
  • Dividend Yield
  • VNRX N/A
  • GANX N/A
  • EPS Growth
  • VNRX N/A
  • GANX N/A
  • EPS
  • VNRX N/A
  • GANX N/A
  • Revenue
  • VNRX $1,319,252.00
  • GANX N/A
  • Revenue This Year
  • VNRX $274.46
  • GANX N/A
  • Revenue Next Year
  • VNRX $212.60
  • GANX N/A
  • P/E Ratio
  • VNRX N/A
  • GANX N/A
  • Revenue Growth
  • VNRX 35.10
  • GANX N/A
  • 52 Week Low
  • VNRX $0.40
  • GANX $1.36
  • 52 Week High
  • VNRX $0.94
  • GANX $3.19
  • Technical
  • Relative Strength Index (RSI)
  • VNRX 46.17
  • GANX 43.33
  • Support Level
  • VNRX $0.57
  • GANX $1.55
  • Resistance Level
  • VNRX $0.73
  • GANX $1.78
  • Average True Range (ATR)
  • VNRX 0.05
  • GANX 0.13
  • MACD
  • VNRX -0.00
  • GANX -0.03
  • Stochastic Oscillator
  • VNRX 37.56
  • GANX 18.00

About VNRX VolitionRX Limited

VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

Share on Social Networks: